Hamlet BioPharma the innovative pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections today launches the new website introducing…
Read More
Pressmeddelande Malmö 17 maj 2023 Vid extra bolagsstämma i Hamlet Pharma AB, org.nr. 556568-8958, (”Hamlet Pharma” eller ”Bolaget”) den 17 maj 2023 fattades följande beslut….
Hamlet Pharma AB (publ) (”Hamlet Pharma” eller ”Bolaget”) emitterade under 2021 teckningsoptioner av serie TO 4 B. Varje teckningsoption ger rätt att teckna en (1)…
In a recent evaluation of Hamlet Pharma, the European Commission concluded that Hamlet Pharma’s bladder cancer project has delivered exceptional results with immediate or potential…
The shareholders of Hamlet Pharma AB (publ) (“Hamlet Pharma” or the “Company”), reg. no. 556568-8958, are hereby invited to the extraordinary general meeting on Wednesday,…
Aktieägarna i Hamlet Pharma AB (publ) (”Hamlet Pharma” eller ”Bolaget”), org.nr 556568-8958, kallas härmed till extra bolagsstämma onsdagen den 17 maj 2023 kl. 14:00 i…
The two pharmaceutical companies Hamlet Pharma AB and SelectImmune Pharma AB, listed on the Spotlight Stock Market, intend to merge and create a powerful pharmaceutical…
PRESSMEDDELANDE, LUND 31 MARS 2023 De båda läkemedelsbolagen Hamlet Pharma AB och SelectImmune Pharma AB, noterade på Spotlight Stock Market, avser att gå samman och…
Hamlet Pharma, listed on Spotlight Stock Market, was awarded an EIC Accelerator grant of 2.2 M EURO in the highly competitive Horizon 2020 program. The…
Opening remarks During the second quarter of the fiscal year, Hamlet Pharma has made significant progress in its clinical trial program for Alpha1H, a drug…
An advertorial by Hamlet Pharma was published in The Guardian on December 6th. Entitled “Successful new drug candidate for patients with bladder cancer – from…
Igår, den 24 november 2022, hölls årsstämma i Hamlet Pharma AB (publ). Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades enhälligt. …